Yesterday, Peking University released a blockbuster news about the treatment of diabetes: Peking University's stem cell research center cooperated with Tianjin First Central Hospital to successfully complete the first international islet cell transplantation operation of Type 1 diabetes subject's chemical reprogramming to induce multipotential stem cell differentiation. The treatment technology is expected to become an ideal scheme to completely cure Type 1 diabetes. The subject receiving islet cell transplantation was a Type 1 diabetes patient with a history of 11 years. On the day of transplantation, the patient returned to normal activity and the pancreatic islet cells survived well. On the 10th day after transplantation, the patient's blood sugar remained stable and their daily insulin requirement had been reduced to half of before transplantation. Deng Hongkui, director of the Stem Cell Research Center of Peking University, revealed that the islet cell function after transplantation will be further mature in patients, and the therapeutic effect will gradually reach a stable state within a few months after transplantation. "We are one of the first teams to transform human pluripotent stem cells into pancreatic and hepatic Cell lineage, and these differentiated cells are being used in cell therapy and the testing of large animal models." Deng Hongkui introduced that based on the research on the development of reprogramming strategies, the team also confirmed for the first time that mature Somatic cell cells can be reprogrammed into pluripotent stem cells completely using small chemical molecules. In March this year, researchers found a new combination of small chemical molecules and established a new chemical reprogramming system for human cells, which can more quickly and efficiently induce human Somatic cell into pluripotent stem cells, and the induction efficiency has also been greatly improved, up to 31%. (Reporter He Rui)